- Correction
- Open access
- Published:
Correction: Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma
Journal of Experimental & Clinical Cancer Research volume 42, Article number: 87 (2023)
The Original Article was published on 19 August 2019
Correction : J Exp Clin Cancer Res 38, 362 (2019)
https://doi.org/10.1186/s13046-019-1348-z
Following publication of the original article [1], the authors identified an error in Fig. 9, specifically:
-
Fig. 9a - the representative IHC figure of LC3B in PH1/HGFK1 + sorefenib group was repetitive to PH1/pVehicle group
The correct figure is given below.
Effect of sorafenib and HGFK1 on the expression of LC3B, phosphorylated NF-κB, CD133, Nanog, and Oct4 in vivo. Tumor tissues from sorafenib and/or HGFK1 treated tumor-bearing mice were collected and stained with IHC. The expression of LC3B and phosphorylated NF-κB (a), as well as CD133, Nanog, and Oct4 (b) on tumor tissues was analyzed and quantified with IOD. All data shown represent the mean ± SD from three to five independent sections. Significant differences are denoted by ** for p < 0.01, and *** for p < 0.001
Reference
Gao X, Jiang P, Zhang Q, et al. Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma. J Exp Clin Cancer Res. 2019;38:362. https://doi.org/10.1186/s13046-019-1348-z.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Gao, X., Jiang, P., Zhang, Q. et al. Correction: Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma. J Exp Clin Cancer Res 42, 87 (2023). https://doi.org/10.1186/s13046-023-02669-2
Published:
DOI: https://doi.org/10.1186/s13046-023-02669-2